Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.67 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.67 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.67 |
| ▸ | GRIA1 | P42261 | 9/20 | 0.63 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.62 |
| ▸ | CHRNG | P07510 | 2/20 | 0.62 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.62 |
| ▸ | CHRND | Q07001 | 2/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.61 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9089141 | 0.96 | CHRND (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL9090677 | 0.88 | CHRNA1 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL9091432 | 0.88 | CHRNA1 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL240780 | 0.88 | CHRNA1 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL7208901 | 0.87 | CHRND (0.60) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL10632109 | 0.87 | CHRND (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL30040212 | 0.83 | CTSL (0.66) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL9089190 | 0.80 | CAPN1 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL10632510 | 0.78 | CHRNA1 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL15224395 | 0.78 | CHRND (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| WO-2007081530-A2 | ENDOLUMINAL MEDICAL DEVICE FOR LOCAL DELIVERY OF CATHEPSIN INHIBITORS | MED INSTITUTE, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | CTSS, CTSD, CTSV | CHRNB2 3556/4885CHRNB4 3970/4885CHRNA3 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.